Table 2.

Risk of prostate cancer associated with duration of use of NSAIDs

Cases (n = 2183)
Controls (n = 10,000)
Model 1a
Model 2b
n (%)n (%)OR (95% CI)OR (95% CI)
Aspirin
    No usec1675 (76.7)7675 (76.8)
    Current use (yr)421 (19.3)1904 (19.0)0.95 (0.84–1.07)0.70 (0.61–0.79)
        0–1111 (5.1)519 (5.2)0.91 (0.74–1.13)0.62 (0.50–0.77)
        1–276 (3.5)331 (3.3)1.01 (0.78–1.31)0.67 (0.51–0.88)
        2–4102 (4.7)490 (4.9)0.92 (0.73–1.15)0.69 (0.55–0.87)
        ≥4132 (6.1)564 (5.6)1.03 (0.84–1.26)0.83 (0.67–1.02)
Test for trend: P = 0.22
NA-NSAIDs
    No usec879 (40.3)4582 (45.8)
    Current use (yr)622 (28.5)2100 (21.0)1.40 (1.24–1.59)1.14 (1.00–1.29)
        0–1453 (20.8)1360 (13.6)1.55 (1.36–1.77)1.26 (1.09–1.45)
        1–238 (1.7)188 (1.9)0.94 (0.66–1.35)0.70 (0.49–1.02)
        2–447 (2.2)203 (2.0)1.09 (0.78–1.52)0.99 (0.70–1.40)
        ≥484 (3.9)349 (3.5)1.16 (0.90–1.49)0.93 (0.71–1.21)
Test for trend: P = 0.12
Paracetamol
    No usec972 (44.5)5009 (50.1)
    Current use (yr)721 (33.0)2510 (25.1)1.33 (1.19–1.49)0.95 (0.84–1.07)
        0–1516 (23.6)1468 (14.7)1.63 (1.43–1.85)1.14 (1.00–1.31)
        1–258 (2.7)255 (2.6)1.04 (0.77–1.40)0.67 (0.49–0.92)
        2–476 (3.5)291 (2.9)1.25 (0.96–1.63)0.87 (0.66–1.15)
        ≥471 (3.3)496 (5.0)0.69 (0.53–0.89)0.50 (0.38–0.65)
Test for trend: P = 0.02
  • a Model 1: Estimates of risk are adjusted for age, calendar year, prior BPH history, and all the variables included in the table using logistic regression.

  • b Model 2 (fully adjusted): Estimates of risk are adjusted for age, calendar year, prior BPH history, number of visits to general practitioners, referrals, hospitalizations, and all the variables included in the table using logistic regression.

  • c Reference category.